IL307822A - Glucagon as peptide compounds - Google Patents
Glucagon as peptide compoundsInfo
- Publication number
- IL307822A IL307822A IL307822A IL30782223A IL307822A IL 307822 A IL307822 A IL 307822A IL 307822 A IL307822 A IL 307822A IL 30782223 A IL30782223 A IL 30782223A IL 307822 A IL307822 A IL 307822A
- Authority
- IL
- Israel
- Prior art keywords
- glucagon
- peptide compounds
- peptide
- compounds
- Prior art date
Links
- 108010088406 Glucagon-Like Peptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21169757 | 2021-04-21 | ||
| PCT/IB2022/053698 WO2022224164A1 (en) | 2021-04-21 | 2022-04-20 | Glucagon like peptide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307822A true IL307822A (en) | 2023-12-01 |
Family
ID=75639721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307822A IL307822A (en) | 2021-04-21 | 2022-04-20 | Glucagon as peptide compounds |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240247042A1 (https=) |
| EP (1) | EP4326330A1 (https=) |
| JP (1) | JP2024514352A (https=) |
| KR (1) | KR20230171471A (https=) |
| CN (1) | CN117202936A (https=) |
| AR (1) | AR125400A1 (https=) |
| AU (1) | AU2022260805A1 (https=) |
| BR (1) | BR112023021597A2 (https=) |
| CA (1) | CA3216058A1 (https=) |
| CL (1) | CL2023003091A1 (https=) |
| IL (1) | IL307822A (https=) |
| MX (1) | MX2023012290A (https=) |
| TW (1) | TW202304500A (https=) |
| WO (1) | WO2022224164A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4048664A1 (en) | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| JP6730278B2 (ja) * | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| MA41580A (fr) * | 2015-01-23 | 2017-11-29 | Novartis Ag | Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée |
-
2022
- 2022-04-19 TW TW111114875A patent/TW202304500A/zh unknown
- 2022-04-20 US US18/556,461 patent/US20240247042A1/en active Pending
- 2022-04-20 IL IL307822A patent/IL307822A/en unknown
- 2022-04-20 WO PCT/IB2022/053698 patent/WO2022224164A1/en not_active Ceased
- 2022-04-20 BR BR112023021597A patent/BR112023021597A2/pt unknown
- 2022-04-20 EP EP22719363.8A patent/EP4326330A1/en active Pending
- 2022-04-20 MX MX2023012290A patent/MX2023012290A/es unknown
- 2022-04-20 JP JP2023564257A patent/JP2024514352A/ja active Pending
- 2022-04-20 KR KR1020237039490A patent/KR20230171471A/ko active Pending
- 2022-04-20 CA CA3216058A patent/CA3216058A1/en active Pending
- 2022-04-20 CN CN202280029619.8A patent/CN117202936A/zh active Pending
- 2022-04-20 AU AU2022260805A patent/AU2022260805A1/en not_active Abandoned
- 2022-04-21 AR ARP220101035A patent/AR125400A1/es unknown
-
2023
- 2023-10-17 CL CL2023003091A patent/CL2023003091A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4326330A1 (en) | 2024-02-28 |
| CL2023003091A1 (es) | 2024-05-03 |
| WO2022224164A1 (en) | 2022-10-27 |
| CA3216058A1 (en) | 2022-10-27 |
| TW202304500A (zh) | 2023-02-01 |
| JP2024514352A (ja) | 2024-04-01 |
| CN117202936A (zh) | 2023-12-08 |
| AR125400A1 (es) | 2023-07-12 |
| BR112023021597A2 (pt) | 2024-02-06 |
| MX2023012290A (es) | 2023-10-26 |
| KR20230171471A (ko) | 2023-12-20 |
| US20240247042A1 (en) | 2024-07-25 |
| AU2022260805A1 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201911928D0 (en) | Pharmaceutical compounds | |
| EP4452937A4 (en) | CONNECTIONS | |
| IL307822A (en) | Glucagon as peptide compounds | |
| GB202020191D0 (en) | Pharmaceutical compounds | |
| GB201911944D0 (en) | Pharmaceutical compounds | |
| GB202010409D0 (en) | Pharmaceutical compounds | |
| GB201915273D0 (en) | Pharmaceutical compounds | |
| GB201914910D0 (en) | Pharmaceutical compounds | |
| GB202010408D0 (en) | Pharmaceutical compounds | |
| GB201915932D0 (en) | Pharmaceutical compounds | |
| IL291570A (en) | Pharmaceutical preparations | |
| GB202111193D0 (en) | Pharmaceutical compounds | |
| GB202108249D0 (en) | Compounds | |
| GB202104097D0 (en) | Pharmaceutical compounds | |
| GB201918693D0 (en) | Peptide | |
| GB202117405D0 (en) | Peptide | |
| HK40102509A (en) | Glucagon like peptide compounds | |
| GB202102602D0 (en) | Pharmaceutical compounds | |
| GB2595608B (en) | Anti-preset for packers | |
| GB202014944D0 (en) | Compounds | |
| ES3063655T3 (en) | Compounds | |
| GB202111675D0 (en) | Peptide | |
| GB202313820D0 (en) | Peptide | |
| GB201912632D0 (en) | Peptide | |
| GB202117969D0 (en) | Pharmaceutical compounds |